EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemotherapy‐Induced Myelosuppression in Patients With gBRCA ‐m Epithelial Ovarian Cancer: A Retrospective Study

Hongtao Hu, Xianglin Nie, Yuxin Jiang, Chaoyi Shi, Xing Chen, Weiyue Zhang, Shan Wu, Yanmei Cheng, Lin Zhang, Yi Jiang, Shulin Zhou, Chengyan Luo iD und 2 weitere

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.03.2026. Verfasst von Hongtao Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Germ-Line Mutation, BRCA1 Protein. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University, Youth Talents Development Program of Jiangsu Women and Children Health Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Existing evidence indicates that germline BRCA mutation (gBRCA‐m) may increase chemotherapy sensitivity and toxicity. However, its role in chemotherapy‐induced myelosuppression (CIM) remains unclear. We conducted this study to investigate the influence of gBRCA‐m on CIM incidence and severity in patients with epithelial ovarian carcinoma (EOC).

Methods

Patients with EOC treated at the First Affiliated Hospital of Nanjing Medical University from January 2018 to August 2023 were classified into two groups: gBRCA‐m and gBRCA wild‐type. Chemotherapy regimen and myelosuppression data were retrospectively reviewed. Multivariate analysis assessed the association between gBRCA‐m and CIM incidence and severity in patients with EOC receiving first‐line chemotherapy.

Results

Sixty six (27%) of 242 included patients were gBRCA‐m carriers. The median times to myelosuppression onset and the most severe occurrence were significantly shorter for patients with gBRCA‐m (6.0 vs. 27.0 days, p < 0.001; 73.5 vs. 121.0 days, p < 0.001). Patients with gBRCA‐m had a greater likelihood of Grade IV (GIV) myelosuppression at onset (aOR = 5.585, 95% CI = 1.621–19.241). During the most severe myelosuppression, patients with gBRCA‐m experienced more pronounced decreases in white blood cells (1.83 × 10 9 vs. 2.33*10 9 cells/L, p = 0.002), neutrophils (0.73 × 10 9 vs. 1.08 × 10 9 cells/L, p = 0.001), haemoglobin levels (90.41 vs. 94.14 g/L, p = 0.017) and platelets (81.62 × 10 9 vs. 97.63 × 10 9 cells/L, p = 0.001) and were more prone to febrile GIV myelosuppression (aOR = 2.882, 95% CI = 1.071–7.754). The incidences of chemotherapy dose reduction (aOR = 4.322, 95% CI = 2.048–9.124) and delay (aOR = 6.045, 95% CI = 2.266–16.126) were significantly greater in patients with gBRCA‐m. An analysis across all chemotherapy cycles indicated that patients with gBRCA‐m had greater risks of GIII (aOR = 2.356, 95% CI = 1.770–3.137), GIV (aOR = 2.324, 95% CI = 1.685–3.207) myelosuppression and GIV myelosuppression with fever (aOR = 2.097, 95% CI = 1.077–4.083), as well as a greater incidence of chemotherapy dose reduction (aOR = 2.606, 95% CI = 1.785–3.805) and delay (aOR = 4.118, 95% CI = 2.213–7.663).

Conclusions

EOC patients with gBRCA‐m experienced earlier and more severe CIM, highlighting the need for careful monitoring and tailored management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Ovarian EpithelialOvarian NeoplasmsGerm-Line MutationBRCA1 ProteinAntineoplastic Combined Chemotherapy ProtocolsBRCA2 ProteinHumansFemaleRetrospective StudiesMiddle AgedAdultAgedCytopenia

Stichwörter der Autor:innen

chemotherapy‐induced myelosuppressionepithelial ovarian carcinomafirst‐line chemotherapygBRCA1/2 mutation

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Gynaecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
  • Department of Reproductive Medicine, Women and Children's Hospital of Ningbo University, Zhejiang, China.
  • Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

ORCID-Profile: Chengyan Luo, Wenjun Cheng

Förderung

  • National Natural Science Foundation of China
  • Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University
  • Youth Talents Development Program of Jiangsu Women and Children Health Hospital
  • Jiangsu Health International Exchange Program sponsorship
  • Ningbo Yong Jiang Talent Programme

Zitieren

APA

Hu, H., Nie, X., Jiang, Y., Shi, C., Chen, X., Zhang, W., Wu, S., Cheng, Y., Zhang, L., Jiang, Y., Zhou, S., Luo, C., Yuan, L., & Cheng, W. (2026). Chemotherapy‐Induced Myelosuppression in Patients With gBRCA ‐m Epithelial Ovarian Cancer: A Retrospective Study. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71724

Vancouver

Hu H, Nie X, Jiang Y, Shi C, Chen X, Zhang W, et al. Chemotherapy‐Induced Myelosuppression in Patients With gBRCA ‐m Epithelial Ovarian Cancer: A Retrospective Study. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71724

BibTeX
@article{Hu2026,
  author = {Hu, Hongtao and Nie, Xianglin and Jiang, Yuxin and Shi, Chaoyi and Chen, Xing and Zhang, Weiyue and Wu, Shan and Cheng, Yanmei and Zhang, Lin and Jiang, Yi and Zhou, Shulin and Luo, Chengyan and Yuan, Lin and Cheng, Wenjun},
  title = {Chemotherapy‐Induced Myelosuppression in Patients With gBRCA ‐m Epithelial Ovarian Cancer: A Retrospective Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71724}
}
Kostenlos starten →